Researchers at the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have discovered a way to give worn-out immune cells a second wind in the fight against ...
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the ...
A newly identified protein may be one of the biggest obstacles holding CAR T-cell therapy back. Researchers found that NFIL3 causes these engineered immune cells to become exhausted and lose their ...
Despite improvements in therapies, multiple myeloma (MM) is a disease that will always relapse. Why is this? What is the key to finding effective therapies to cure MM? Evan Newell, a Professor in the ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Left: UMAP projections of CD8⁺/WPRE⁺ (adoptive T cells) and CD8⁺/WPRE⁻ (endogenous T cells) cells mapped onto a reference TIL atlas reveal a reduced prevalence of exhausted CD8⁺ T cells and enrichment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results